P

PeterLabs Holdings Bhd
KLSE:PLABS

Watchlist Manager
PeterLabs Holdings Bhd
KLSE:PLABS
Watchlist
Price: 0.285 MYR 7.55% Market Closed
Market Cap: 78.4m MYR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one PLABS stock under the Base Case scenario is 0.257 MYR. Compared to the current market price of 0.285 MYR, PeterLabs Holdings Bhd is Overvalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PLABS Relative Value
Base Case
0.257 MYR
Overvaluation 10%
Relative Value
Price
P
Worst Case
Base Case
Best Case

Valuation Multiples

0.4
P/S
P/S
Price to Sales
0.4
vs History
22
vs Industry
88
Median 3Y
0.3
Median 5Y
0.3
Industry
2.4
More Details
27.6
P/E
P/E
Price to Earnings
27.6
vs History
0
vs Industry
27
Median 3Y
15.6
Median 5Y
13.8
Industry
20.6
More Details
8.2
P/OCF
P/OCF
Price to OCF
8.2
vs History
44
vs Industry
47
Median 3Y
8.9
Median 5Y
6.7
Industry
15.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
25
Median 3Y
-6.5
Median 5Y
2.9
Industry
23
More Details
1
P/B
P/B
Price to Book Value
1
vs History
0
vs Industry
69
Median 3Y
0.7
Median 5Y
0.7
Industry
1.9
More Details
0.4
EV/S
EV/S
Enterprise Value to Sales
0.4
vs History
3
vs Industry
90
Median 3Y
0.2
Median 5Y
0.3
Industry
2.5
More Details
3.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.1
vs History
0
vs Industry
72
Median 3Y
1.8
Median 5Y
1.8
Industry
4.9
More Details
14.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
14.7
vs History
0
vs Industry
35
Median 3Y
6.9
Median 5Y
5.7
Industry
12.6
More Details
14.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
14.7
vs History
0
vs Industry
40
Median 3Y
7.4
Median 5Y
5.7
Industry
15.7
More Details
7.3
EV/OCF
EV/OCF
Enterprise Value to OCF
7.3
vs History
39
vs Industry
50
Median 3Y
7.3
Median 5Y
5.6
Industry
14
More Details
41.1
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
41.1
vs History
4
vs Industry
19
Median 3Y
9.8
Median 5Y
7.3
Industry
17.7
More Details
0.7
EV/IC
EV/IC
Enterprise Value to IC
0.7
vs History
0
vs Industry
76
Median 3Y
0.5
Median 5Y
0.5
Industry
1.8
More Details

Multiples Across Competitors

PLABS Competitors Multiples
PeterLabs Holdings Bhd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
MY
PeterLabs Holdings Bhd
KLSE:PLABS
78.4m MYR 0.4 27.6 14.7 14.7
US
Eli Lilly and Co
NYSE:LLY
838.1B USD 18.6 79.1 45.9 50.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.1B USD 4.2 17.1 12.4 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.2 17.7 11.7 13.4
CH
Roche Holding AG
SIX:ROG
208.3B CHF 3.4 25.2 9.5 11.1
CH
Novartis AG
SIX:NOVN
187.4B CHF 4.4 19 11.5 14.7
UK
AstraZeneca PLC
LSE:AZN
161.3B GBP 4 30.5 126.2 192.7
US
Merck & Co Inc
NYSE:MRK
209.1B USD 3.3 12 8.6 10.3
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
FR
Sanofi SA
PAR:SAN
115.8B EUR 1.3 9.1 5 5.9
P/E Multiple
Earnings Growth PEG
MY
P
PeterLabs Holdings Bhd
KLSE:PLABS
Average P/E: 26.4
27.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
79.1
49%
1.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
17.7
18%
1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.5
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
FR
Sanofi SA
PAR:SAN
9.1
28%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
MY
P
PeterLabs Holdings Bhd
KLSE:PLABS
Average EV/EBITDA: 395.7
14.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
45.9
31%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.4
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.7
14%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
CH
Novartis AG
SIX:NOVN
11.5
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
126.2
9%
14
US
Merck & Co Inc
NYSE:MRK
8.6
9%
1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5
8%
0.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
MY
P
PeterLabs Holdings Bhd
KLSE:PLABS
Average EV/EBIT: 1 698.8
14.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
50.7
33%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
CH
Novartis AG
SIX:NOVN
14.7
8%
1.8
UK
AstraZeneca PLC
LSE:AZN
192.7
21%
9.2
US
Merck & Co Inc
NYSE:MRK
10.3
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

See Also

Summary
PLABS intrinsic value, competitors valuation, and company profile.
DCF Valuation
PLABS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PLABS stock valuation using valuation multiples.
Wall Street Estimates
PLABS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PLABS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 249,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.